<DOC>
	<DOCNO>NCT02753699</DOCNO>
	<brief_summary>The purpose study follow-up participant feeder study achieve sustain virologic response ( SVR ) 24 hour posttreatment ( SVR24 ) , assess durability SVR , ass change liver disease , development hepatocellular carcinoma post-treatment safety time . Participants enter study feeder study CDEB025A2210 ( NCT01183169 ) , CDEB025A2301 ( NCT01318694 ) , CDEB025A2211 ( NCT01215643 ) . They return site 48 week maximum 3 visit . No treatment involve .</brief_summary>
	<brief_title>Long Term Follow-up Study Assess Durability Sustained Virologic Response Alisporivir-treated Hepatitis C Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>1 . Provides write informed consent assessment perform 2 . Is male female age â‰¥18 3 . Has previously complete Novartissponsored hepatitis C study receive alisporivir 4 . Has achieve SVR24 5 . Is able comply visit schedule 1 . Use investigational drug within 5 halflives enrollment , within 30 day medication , whichever longer . 2 . Use plan use start new course hepatitis C therapy . 3 . No additional exclusion apply Investigator , order ensure study population representative eligible patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
</DOC>